低剂量灌注计算机断层扫描用于乳腺癌肿瘤血管性定量:与预后生物标志物的相关性
这项初步研究纳入70例浸润性乳腺癌患者,采用俯卧位低剂量灌注CT(80 kVp、30 mAs,1.30–1.40 mSv)测量肿瘤及正常腺体、脂肪的灌注指标,并与组织病理学预后标志物及MRI强化特征进行相关性分析。结果显示肿瘤灌注、血容量和强化峰值强度显著高于正常腺体与脂肪,且灌注指标与肿瘤分级、ER、HER2、Ki67及MRI廓清强化模式显著相关。
要点
- 乳腺癌低剂量灌注CT表现为灌注、血容量和强化峰值强度显著高于正常腺体及脂肪,达峰时间缩短。
- 高分级、ER阴性或HER2阳性乳腺癌灌注显著增高,达峰时间缩短。
- HER2过表达型乳腺癌灌注高于Luminal型且达峰时间更短,MRI廓清强化模式者灌注增高、达峰时间缩短。
核心结论
- 俯卧位低剂量灌注CT可量化乳腺癌肿瘤血管性,其灌注指标与预后生物标志物及分子亚型显著相关。
研究设计与样本
- 初步研究,纳入70例浸润性乳腺癌患者,采用光谱CT设备于80 kVp、30 mAs(1.30–1.40 mSv)行俯卧位低剂量灌注CT,使用最大斜率算法分析,以组织病理学(肿瘤分级、ER、HER2、Ki67)及MRI强化特征为参考。
关键影像表现/征象
- 乳腺癌灌注、血容量和强化峰值强度显著高于正常腺体组织和脂肪,达峰时间缩短(P < 0.001)。
- 高分级、ER阴性或HER2阳性乳腺癌灌注显著增高(P < 0.05)。
- ER阴性、HER2阳性、高分级或高Ki67水平乳腺癌达峰时间缩短(P < 0.05)。
- 高分级乳腺癌强化峰值强度显著增高(P < 0.05)。
- HER2过表达型乳腺癌灌注显著高于Luminal型且达峰时间更短(P < 0.05)。
诊断标准与关键数值
- 灌注指标包括灌注(mL/min per 100 mL)、血容量(mL/100 g)、达峰时间(秒)和强化峰值强度(HU)。
- 肿瘤分级、ER、HER2和Ki67水平采用组织病理学评估。
- MRI强化特征用于与CT灌注指标进行相关性分析。
临床应用与阅片要点
- 俯卧位低剂量灌注CT可用于乳腺癌肿瘤血管性定量评估。
- 灌注指标与预后生物标志物及分子亚型相关,阅片时可结合灌注、血容量、达峰时间和强化峰值强度综合解读。
- MRI廓清强化模式对应CT灌注增高和达峰时间缩短,可作为影像学关联参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to investigate the feasibility of using low-dose perfusion computed tomography (CT) in breast cancers for quantification of tumor vascularity and to correlate perfusion indexes with prognostic biomarkers.
MATERIALS AND METHODS: This preliminary study was approved by our institutional review board. Signed informed consent was obtained from all 70 enrolled patients with invasive breast cancers. Low-dose perfusion CT was performed with the patient in the prone position using a spectral CT device set at 80 kVp and 30 mAs (1.30-1.40 mSv). Images were analyzed using commercial software applying the maximum slope algorithm. On CT perfusion maps, perfusion (mL/min per 100 mL), blood volume (mL/100 g), time-to-peak enhancement (second), and peak enhancement intensity (HU) were measured in the tumor, normal breast glandular tissues, and fat. Tumor grade, estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and Ki67 level were evaluated using histopathology. Statistically, CT perfusion indexes of the tumor and normal glandular tissues or fat were compared using the Wilcoxon signed-rank test, and CT indexes were correlated with histological characteristics using the Mann-Whitney U or Kruskal-Wallis tests. We also correlated CT indexes with magnetic resonance imaging enhancement characteristics.
RESULTS: In breast cancers, perfusion, blood volume, and peak enhancement intensity values were significantly higher, and time to peak was shorter than in normal glandular tissues and fat (P < 0.001). Perfusion increased significantly in high-grade, ER-, or HER2+ cancers (P < 0.05). Time to peak decreased in ER-, HER2+, and high-grade cancers or in those with high Ki67 levels (P < 0.05). Peak enhancement intensity significantly increased in high-grade cancers (P < 0.05). HER2 overexpressing cancers showed significantly higher perfusion and shorter time to peak than luminal-type cancers (P < 0.05). Perfusion increased and time to peak decreased significantly in cancers with washout enhancement patterns on magnetic resonance imaging.
CONCLUSIONS: Low-dose perfusion CT in the prone position is feasible to quantify tumor vascularity in breast cancers, and CT perfusion indexes are significantly correlated with prognostic biomarkers and molecular subtypes of breast cancer.
引用
- Park EK, Seo BK, Kwon M, et al. Low-Dose Perfusion Computed Tomography for Breast Cancer to Quantify Tumor Vascularity: Correlation With Prognostic Biomarkers. Invest Radiol. 2019. PMID: 30570503. doi:10.1097/RLI.0000000000000538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。